30th May 2022 12:32
Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Posts higher annual loss in 2021. Pretax loss widens to GBP4.0 million from GBP14,000 in 2020. In May 2021, Cizzle was bought by Bould Opportunities PLC. Acquisition-related costs stand at GBP3.1 million in 2021 versus none in 2020.
Net assets grow to GBP1.2 million from GBP10,000 in 2020. The company does not make any revenue. Firm expects "to create a range of monoclonal antibodies and reagents" regarding its lung-cancer focused collaboration with Portugal-based FairJourney Biologics. Cizzle aims to develop blood tests for the early detection of lung cancer, it explains.
Current stock price: 1.85 pence, up 2.8% on Monday
12-month change: down 74%
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Cizzle Biotech